Genetic variants associated with D-dimer levels in children born to mothers with recurrent pregnancy loss

In the complex machinery of the human body, blood clotting is a vital defense system. It acts as a sealant, stopping bleeding when a vessel is damaged, yet it must remain fluid enough to circulate freely under normal conditions. When this balance tips too far toward clotting, a condition known as thrombophilia, the blood becomes prone to forming dangerous clots inside veins. This risk can be inherited, passed down through genes that dictate how the body manages these clotting factors. For decades, doctors have known that certain genetic variations make adults more susceptible to these events, but a quieter question has lingered: does a mother's history of pregnancy loss leave a mark on her child's own blood system, even if that child is born healthy and grows up without immediate symptoms?

This question sits at the intersection of obstetrics and pediatric medicine. Recurrent pregnancy loss, where a woman experiences multiple miscarriages, is often linked to blood clotting issues within the mother. The theory is that the same factors causing trouble in the womb might influence the developing fetus, potentially programming the child's hemostasis—the system that controls bleeding and clotting—to be more reactive. While researchers have studied how genetics affect clotting in children with serious illnesses like cancer, the specific link between a mother's difficult pregnancy history and the blood health of her surviving children has remained largely unexplored.

A team of researchers set out to investigate this connection by looking at a specific group of children: those born to mothers with a history of recurrent miscarriage. They focused on three specific genetic variants known to influence clotting, along with two key measurements of blood health. The first measurement, D-dimer, acts as a signal of how much clotting and breaking down of clots is happening inside the body at any given time; higher levels suggest the system is working harder than usual. The second, the INR, measures how long it takes for blood to clot, reflecting the activity of the external clotting pathway. The researchers wanted to see if the children's genetic makeup directly influenced these numbers, and if the history of their mothers' miscarriages made these genetic effects stronger.

To find the answers, the scientists gathered data on 352 children, aged seven to fourteen, whose mothers had a history of miscarriage. They compared this group against 261 healthy children whose mothers had no such history. Over the course of a year, the team measured the children's D-dimer and INR levels every single month, calculating an average for each child to smooth out daily fluctuations. They also analyzed the children's DNA to determine which versions of three specific genes they carried: one related to a protein called Factor V, and two related to proteins on the surface of platelets, the tiny cell fragments that help form clots.

The results revealed a clear story about how genetics and family history interact. The researchers found that children carrying a specific variation in the Factor V gene had significantly higher D-dimer levels than those without it. This effect was strong and consistent, appearing in both the group of children with a history of miscarriage and the healthy control group. However, the story changed for the second gene they studied, which affects platelet behavior. For this gene, the genetic variation only showed a strong effect in the children whose mothers had experienced miscarriages. In this high-risk group, the D-dimer levels rose in a predictable step-like pattern depending on which version of the gene the child inherited, with one specific version leading to the highest levels. In the healthy control group, this same genetic variation made no difference at all.

The third gene they examined did not show a reliable connection to D-dimer levels in either group, suggesting it plays a minor role in this specific context. Furthermore, the study found that none of these genetic variations had any noticeable impact on the INR, the measure of how long clotting takes. This distinction is important because it suggests that the genetic factors influencing a child's risk are more about the active turnover of clots inside the blood vessels, rather than the initial speed at which a clot forms.

When the researchers combined all the data into a single analysis, the picture became even sharper. They confirmed that both the Factor V variation and the platelet-related variation were independently linked to higher D-dimer levels. The most powerful factor, however, was simply belonging to the group of children born to mothers with a history of miscarriage. These children had a risk of having elevated D-dimer levels (above the clinical threshold of 550 ng/mL) that was more than six times higher than that of the control group. The presence of the specific genetic variations acted as a multiplier, pushing the levels even higher within this already elevated group.

The study concludes that while these genetic markers are not a universal screening tool for all children, they are significant indicators for a specific subset of the population. For children born to mothers who have struggled with recurrent pregnancy loss, carrying these specific genetic variations appears to create a state of "thrombotic readiness," where the blood is primed to clot more aggressively. The findings suggest that the environment of a pregnancy complicated by clotting issues may interact with a child's inherited genes to shape their long-term blood health. While the study does not recommend routine genetic testing for every child, it highlights that for this particular group, understanding their genetic makeup alongside their blood markers could provide a clearer picture of their health risks. The research underscores that the legacy of a mother's pregnancy challenges can echo into the next generation, not just as a memory, but as a measurable biological reality.